Xencor (DB:XE9) - Stock Price, News & Analysis

XE9 Stock Overview

A clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. More details

XE9 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 29.23% per year

Risk Analysis

Volatile share price over the past 3 months compared to the German market

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Xencor, Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

MorphoSys

HMSE:MOR

€2.6b

Formycon

XTRA:FYB

€818.4m

Heidelberg Pharma

XTRA:HPHA

€106.3m

Price History & Performance

Summary of all time highs, changes and price drops for Xencor
Historical stock prices
Current Share Price	US$21.40
52 Week High	US$24.00
52 Week Low	US$13.90
Beta	0.66
11 Month Change	12.04%
3 Month Change	49.65%
1 Year Change	28.14%
33 Year Change	-33.25%
5 Year Change	-37.79%
Change since IPO	254.25%

Recent updates

Shareholder Returns

	XE9	DE Biotechs	DE Market
7D	0.9%	-1.0%	-0.2%
1Y	28.1%	-16.7%	8.3%

Return vs Industry: XE9 exceeded the German Biotechs industry which returned -18.1% over the past year.

Return vs Market: XE9 exceeded the German Market which returned 9.6% over the past year.

Price Volatility

Is XE9's price volatile compared to industry and market?
XE9 volatility
XE9 Average Weekly Movement	8.9%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: XE9's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: XE9's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1997	280	Bassil Dahiyat	www.xencor.com

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types.

Xencor, Inc. Fundamentals Summary

How do Xencor's earnings and revenue compare to its market cap?
XE9 fundamental statistics
Market cap	€1.56b
Earnings (TTM)	-€188.31m
Revenue (TTM)	€80.90m

19.0x

P/S Ratio

-8.1x

P/E Ratio

Is XE9 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XE9 income statement (TTM)
Revenue	US$85.16m
Cost of Revenue	US$239.68m
Gross Profit	-US$154.51m
Other Expenses	US$43.73m
Earnings	-US$198.24m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.83
Gross Margin	-181.43%
Net Profit Margin	-232.77%
Debt/Equity Ratio	2.5%

How did XE9 perform over the long term?

See historical performance and comparison

XE9 Stock Overview

Rewards

Risk Analysis

Xencor, Inc. Competitors

XTRA:BIO3

€1.4b

HMSE:MOR

€2.6b

XTRA:FYB

€818.4m

XTRA:HPHA

€106.3m

Price History & Performance

Recent News & Updates

Now 22% overvalued after recent price rise

Third quarter 2024 earnings released: US$0.70 loss per share (vs US$0.40 loss in 3Q 2023)

Xencor, Inc. Doses First Subject in Phase 1/2 Study of XmAb®?942 in Development for Patients with Inflammatory Bowel Disease

Now 22% overvalued after recent price rise

Xencor Announces Dagmar Rosa-Bjorkeson Not Stand for Re-Election as Director

Now 24% overvalued after recent price rise

Recent updates

Now 22% overvalued after recent price rise

Third quarter 2024 earnings released: US$0.70 loss per share (vs US$0.40 loss in 3Q 2023)

Xencor, Inc. Doses First Subject in Phase 1/2 Study of XmAb®?942 in Development for Patients with Inflammatory Bowel Disease

Now 22% overvalued after recent price rise

Xencor Announces Dagmar Rosa-Bjorkeson Not Stand for Re-Election as Director

Now 24% overvalued after recent price rise

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Now 28% undervalued after recent price drop

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$1.07 loss per share (vs US$0.37 loss in 2Q 2023)

First quarter 2024 earnings released: US$1.11 loss per share (vs US$1.02 loss in 1Q 2023)

New minor risk - Shareholder dilution

Xencor Appoints Bart Cornelissen as Senior Vice President

Co-Founder recently sold €270k worth of stock

New minor risk - Profitability

Full year 2023 earnings released: US$2.08 loss per share (vs US$0.93 loss in FY 2022)

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Third quarter 2023 earnings released: US$0.40 loss per share (vs US$0.55 loss in 3Q 2022)

Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor Announces Planned Retirement of Senior Vice President John Kuch

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.57 loss in 2Q 2022)

Xencor, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Insufficient new directors

First quarter 2023 earnings released: US$1.02 loss per share (vs US$0.40 profit in 1Q 2022)

Co-Founder recently sold €172k worth of stock

Full year 2022 earnings released: US$0.93 loss per share (vs US$1.42 profit in FY 2021)

Xencor, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Senior VP & Chief Medical Officer recently sold €95k worth of stock

Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual Meeting

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$0.69 loss in 3Q 2021)

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

Xencor, Inc. to Report Q3, 2022 Results on Nov 07, 2022

High number of new directors

Xencor, Inc. to Present Seven Posters on Multiple Clinical Trials and Research-Stage Programs At the SITC Annual Meeting

High number of new directors

Xencbor, Inc. Announces the Appointment of Nancy Valente to Its Board of Directors

Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.90 profit in 2Q 2021)

Xencor, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Investor sentiment improved over the past week

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive Index

Investor sentiment improved over the past week

Xencor, Inc. Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

First quarter 2022 earnings released: EPS: US$0.40 (vs US$0.043 loss in 1Q 2021)

Co-Founder recently sold €65k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Xencor, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR).

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.22 loss in 3Q 2020)

Director Yujiro Hata has joined 3rd company board

Second quarter 2021 earnings released: EPS US$0.90 (vs US$0.61 loss in 2Q 2020)

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 3000E Value Index

Sotrovimab Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19

First quarter 2021 earnings released: US$0.043 loss per share (vs US$0.14 loss in 1Q 2020)